Compare Globus Medical Inc. Class A Common Stock (GMED) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Genuine Parts Company — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Genuine Parts Company trades at $131.49 (market cap $18.02B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.25% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Genuine Parts Company for 75 Days on average.
| GMED | GPC | |
|---|---|---|
Market Cap | $10.25B | $18.02B |
Volume | 1,108,124 | 744,000 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $149.26 |
52-Week Low | $58.33 | $92.47 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $9.76B | $24.11B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
GPC trades at $131.63, up 1.55% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss, while net income margin remains thin at 0.13%. The company is progressing with its planned separation into automotive and industrial businesses by Q1 2027, a key strategic move highlighted in recent news.
The outlook is cautiously optimistic, supported by the corporate split catalyst and steady revenue growth, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though valuation metrics like a high P/E of 522.84 warrant attention for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
